Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009390 | 0.93 | FFAR1 (0.40) | FFAR1PPARDPPARGPPARA | |
| SCHEMBL1708612 | 0.91 | SMN1; SMN2 (0.38) | LMNAFFAR1PDCD1CD274SMN1; SMN2 | |
| SCHEMBL1708299 | 0.83 | FFAR1 (0.42) | LMNAFFAR1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1708614 | 0.79 | LMNA (0.39) | LMNAFFAR1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL1708301 | 0.77 | SMN1; SMN2 (0.41) | LMNAPDCD1CD274SMN1; SMN2NPC1 | |
| SCHEMBL1708164 | 0.76 | FFAR1 (0.37) | LMNAFFAR1PDCD1CD274SMN1; SMN2 | |
| SCHEMBL10291778 | 0.76 | FFAR1 (0.39) | FFAR1PDCD1CD274PPARD | |
| SCHEMBL10291337 | 0.76 | TSHR (0.39) | LMNAFFAR1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1708103 | 0.75 | FFAR1 (0.39) | FFAR1PDCD1CD274PPARDPPARG | |
| SCHEMBL10291219 | 0.75 | FFAR1 (0.40) | FFAR1PDCD1CD274PPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | LMNA 4537/4885FFAR1 20/4885PDCD1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.